{"schema_version":"secwatch.filing_event.v1","accession":"0001821586-24-000028","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.833885+00:00","generated_at":"2026-05-30T03:46:51.769874+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MoonLake Q3 cash $493.9M; Phase 3 HS readout on track for mid-2025","bullets":["Cash, equivalents and short-term debt securities of $493.9M as of Sep 30; runway to end of 2026.","R&D expenses of $35.7M in Q3, up from $23.7M prior quarter, driven by Phase 3 HS ramp-up.","Phase 3 VELA program in HS actively enrolling; primary endpoint readout anticipated as of mid-2025.","Phase 3 PsA program (IZAR-1 and IZAR-2) enrollment expected to commence imminently.","Additional Phase 2 trials in PPP, axSpA, and Phase 3 adolescent HS to start around year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001821586-24-000028","json":"https://secwatch.observer/filing/0001821586-24-000028.json","markdown":"https://secwatch.observer/filing/0001821586-24-000028.md","text":"https://secwatch.observer/filing/0001821586-24-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000182158624000028/0001821586-24-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000182158624000028/mnlk-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:46:51.769874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}